Once-a-month fitusiran reduces bleeding rates in patients with hemophilia A and B with inhibitors

1. Annualized bleeding rate was reduced by 91% in the fitusiran prophylaxis group compared to the bypassing agents on-demand group. 2. 5% of patients in the fitusiran group reported thromboembolic events; there were no deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Hemophilia is marked by a deficiency in certain coagulation factors that make patients

Related Keywords

,Rating Level ,Efanesoctocog Alfa Prophylaxis ,Severe Hemophilia ,Between Feb ,Bleeding ,Fitusiran ,Hematology ,Hemophilia ,Hemophilia A ,Hemophilia B ,Hemostasis ,Major Bleeding ,Chronic Disease ,